- Home
- UGI vs ROIV Comparison
UGI vs ROIV Comparison
Compare UGI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGI
- ROIV
- Stock Information
- Founded
- UGI 1940
- ROIV 2014
- Country
- UGI United States
- ROIV United Kingdom
- Employees
- UGI N/A
- ROIV N/A
- Industry
- UGI Natural Gas Distribution
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- UGI Utilities
- ROIV Health Care
- Exchange
- UGI Nasdaq
- ROIV Nasdaq
- Market Cap
- UGI 6.9B
- ROIV 8.4B
- IPO Year
- UGI N/A
- ROIV N/A
- Fundamental
- Price
- UGI $35.59
- ROIV $10.91
- Analyst Decision
- UGI Buy
- ROIV Buy
- Analyst Count
- UGI 3
- ROIV 4
- Target Price
- UGI $31.33
- ROIV $17.50
- AVG Volume (30 Days)
- UGI 1.8M
- ROIV 5.5M
- Earning Date
- UGI 05-07-2025
- ROIV 05-29-2025
- Dividend Yield
- UGI 4.21%
- ROIV N/A
- EPS Growth
- UGI N/A
- ROIV N/A
- EPS
- UGI 2.46
- ROIV N/A
- Revenue
- UGI $7,318,000,000.00
- ROIV $122,585,000.00
- Revenue This Year
- UGI $6.20
- ROIV N/A
- Revenue Next Year
- UGI $8.02
- ROIV N/A
- P/E Ratio
- UGI $14.44
- ROIV N/A
- Revenue Growth
- UGI N/A
- ROIV 140.04
- 52 Week Low
- UGI $22.01
- ROIV $8.73
- 52 Week High
- UGI $36.35
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- UGI 67.46
- ROIV 52.03
- Support Level
- UGI $33.97
- ROIV $10.58
- Resistance Level
- UGI $36.35
- ROIV $11.77
- Average True Range (ATR)
- UGI 0.66
- ROIV 0.33
- MACD
- UGI 0.17
- ROIV -0.04
- Stochastic Oscillator
- UGI 77.25
- ROIV 28.57
About UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.